Effect of escalating doses of docetaxel on chemoresistant-related gene expression of laryngeal cancer cells
Laryngeal cancer is a sub-type of head and neck cancer, and its treatment frequently entails the use of chemotherapy drugs like docetaxel. Nevertheless, the development of docetaxel resistance mechanisms presents a substantial challenge. Analyzing the transcriptome has become a fundamental approach for understanding the underlying molecular factors contributing to resistance and for pinpointing potential treatment targets. This type of analysis provides a comprehensive overview of the changes in gene expression that occur in laryngeal cancer cells that have become resistant to docetaxel. By comparing the transcriptomes of resistant and sensitive cells, we can identify potential biomarkers and targets for therapy. We have effectively created a laryngeal cancer cell line that is resistant to docetaxel, as evidenced by the increased expression of genes associated with various processes, such as microtubules (TUBB3, EML4ALK), receptors (TRK, PDGFR, GPCR, NOTCH), epithelial adherence (CDH1), metabolism (PIK3CA, DEPTOR, GSK-3ß, PLCß, CYP24A1), hypoxia (HIF-1a, HIF-1ß), apoptosis (TNFRSF11A, p21, MDM2), cytokine production (STAT2/4/6, iNOS, IL-6, IL-8, GMCSFR) and autophagy (CFLAR, GABARAP, ATG4A, RasGEF). Taken together, our data provide a framework that encompasses therapeutic targets for inhibition of upregulated gene expression of docetaxel resistance on laryngeal cancer cells. Overall design: To engineer a docetaxel-resistant laryngeal cancer cell line (DR-LSCC), we expose a commercially available laryngeal cancer cell line with escalating doses of docetaxel up to 4 months We then performed gene expression profiling analysis using data obtained from RNSA-seq of 5 samples of DR-LSCC and two non-resistant cell controls (laryngeal cancer and laryngeal epithelia) Comparative gene expression profiling analysis of RNA-seq data of DR-LSCC compared to non-resistant controls of laryngeal cancer (LSCC) and laryngeal epithelia (LSEC)